South Building, Level 4
2301 South King Dr.
Chicago, IL 60616
1:00 PM: Registration and Lunch
1:15 PM: Welcome and Introduction
1:20 PM: A Closer Look at DSAs as Mediators of Allograft Injury
1:45 PM: Striking the Right Balance: What Can We Do to Achieve and Maintain Adequate Immunosuppression After Kidney Transplantation?
2:10 PM: Q&A and Concluding Remarks
Production of de novo donor-specific antibodies (dnDSA) is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after kidney transplantation, and current understanding suggests that inadequate immunosuppression is the major cause of DSA development and attendant pathology. Calcineurin inhibitors (CNIs) are the mainstay for maintenance immunosuppressive therapy in renal transplantation, with tacrolimus being the most widely used. However, CNIs have a narrow therapeutic window and a high degree of inter- and intra-patient pharmacokinetic variation, which present a challenge when trying to achieve optimal dosing. Consequently, therapeutic drug monitoring is required in order to adjust treatment in individual patients.
Join us for a live lunch symposium that will examine contemporary, evidence-based strategies to minimize late renal allograft failure via optimizing immunosuppressive therapy. Our faculty experts will take a closer look at DSA as mediators of allograft injury, while providing practical guidance on what clinicians can do to achieve and maintain adequate immunosuppression in individual kidney transplant recipients.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of nephrologists, transplant surgeons, and other clinicians involved in the care of kidney transplant recipients.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the
Release and Expiration Date: April 30, 2017
Time to Complete: 60 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.
Stanley C. Jordan, MD, FASN
Professor of Pediatrics & Medicine
David Geffen School of Medicine at UCLA
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, California
Alexander Wiseman, MD, FAST
Professor of Medicine, Division of Renal Diseases and Hypertension
Medical Director, Kidney and Pancreas Transplant Programs
University of Colorado School of Medicine
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Astellas.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.